Renaissance Technologies’s Repare Therapeutics RPTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-981,360
| Closed | -$2.55M | – | 3621 |
|
|
2025
Q4 | $2.55M | Buy |
981,360
+257,200
| +36% | +$518K | ﹤0.01% | 1716 |
|
|
2025
Q3 | $1.27M | Buy |
724,160
+201,301
| +39% | +$322K | ﹤0.01% | 2358 |
|
|
2025
Q2 | $727K | Buy |
522,859
+224,198
| +75% | +$292K | ﹤0.01% | 2658 |
|
|
2025
Q1 | $294K | Sell |
298,661
-48,799
| -14% | -$58.8K | ﹤0.01% | 2931 |
|
|
2024
Q4 | $455K | Sell |
347,460
-106,240
| -23% | -$316K | ﹤0.01% | 2886 |
|
|
2024
Q3 | $1.56M | Sell |
453,700
-5,000
| -1% | -$16.5K | ﹤0.01% | 2173 |
|
|
2024
Q2 | $1.51M | Buy |
458,700
+107,700
| +31% | +$384K | ﹤0.01% | 2057 |
|
|
2024
Q1 | $1.65M | Sell |
351,000
-4,826
| -1% | -$30.9K | ﹤0.01% | 2153 |
|
|
2023
Q4 | $2.6M | Buy |
355,826
+202,926
| +133% | +$1.14M | ﹤0.01% | 1783 |
|
|
2023
Q3 | $1.85M | Buy |
152,900
+7,000
| +5% | +$72.3K | ﹤0.01% | 1918 |
|
|
2023
Q2 | $1.54M | Sell |
145,900
-84,100
| -37% | -$867K | ﹤0.01% | 2169 |
|
|
2023
Q1 | $2.26M | Buy |
230,000
+66,600
| +41% | +$764K | ﹤0.01% | 1952 |
|
|
2022
Q4 | $2.4M | Buy |
163,400
+28,279
| +21% | +$423K | ﹤0.01% | 1960 |
|
|
2022
Q3 | $1.64M | Sell |
135,121
-45,779
| -25% | -$589K | ﹤0.01% | 2157 |
|
|
2022
Q2 | $2.53M | Buy |
180,900
+92,800
| +105% | +$1.09M | ﹤0.01% | 2020 |
|
|
2022
Q1 | $1.25M | Buy |
88,100
+1,400
| +2% | +$20.8K | ﹤0.01% | 2574 |
|
|
2021
Q4 | $1.83M | Buy |
86,700
+69,900
| +416% | +$1.65M | ﹤0.01% | 2211 |
|
|
2021
Q3 | $441K | Sell |
16,800
-3,600
| -18% | -$116K | ﹤0.01% | 2933 |
|
|
2021
Q2 | $636K | Buy |
+20,400
| New | +$668K | ﹤0.01% | 2866 |
|
Renaissance Technologies's RPTX Position: Q1 2026 in Review
Renaissance Technologies sold out of Repare Therapeutics (RPTX) in Q1 2026, closing a stake of 981,360 shares — an estimated $2.55M sold.
Renaissance Technologies first reported a position in RPTX in Q2 2021 and held it in 19 quarters. The position peaked at $2.6M in Q4 2023. 0 funds tracked by Wall St. Rank hold RPTX as of Q1 2026.
- Renaissance Technologies reported no remaining Repare Therapeutics position as of Q1 2026 after selling out during the quarter.
- Renaissance Technologies sold 981,360 Repare Therapeutics shares in Q1 2026, an estimated $2.55M.
- Renaissance Technologies first reported a position in Repare Therapeutics in Q2 2021 and held it in 19 quarters.
- Renaissance Technologies's Repare Therapeutics position peaked at $2.6M in Q4 2023.
- 0 funds tracked by Wall St. Rank held Repare Therapeutics as of Q1 2026.
Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.